

no persons are required to sign

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	10/757,201
Filing Date	01-14-2004
First Named Inventor	ROSSKAMP
Group Art Unit	1654
Examiner Name	HEMANT KHANNA
Attorney Docket Number	USAV2003/0012 - US - NP

*(use as many sheets as necessary)*

Sheet 1 of 2

[illegible][illegible]Date  
Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/757,201
		Filing Date	01-14-2004
		First Named Inventor	ROSSKAMP
		Group Art Unit	1654
		Examiner Name	HEMANT KHANNA
		Attorney Docket Number	USAV2003/0012 - US - NP
Sheet	2	of	2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/H.K./		ROSENSTOCK, J., et. al, Basal Insulin Therapy in Type 2 Diabetes: 28-week Comparison of Insulin Glargine (HOE 901) and NPH Insulin, Abstract XP002282639 Medline Diabetes Care Apr 2001 VOL.24, NO.4 PP.631-636	
/H.K./		THOMAS, M., et. al., Evaluation of the Safety, Efficacy and Tolerability of Insulin Glargine in Subjects with Impaired fasting Glucose, Impaired Glucose Tolerance or New-Onset Type 2 Diabetes, Abstract Biosis/Biosis Vol.52, No.Supplement 1, 2003 pp. A451-A452 XP002282638	
/H.K./		TURNER, R., et. al. Beta-Cell function Improved by Supplementing Basal Insulin Secretion in Mild Diabetes, British Medical Journal 22 May1976, Vol.1, No.6020 pp.1252-1254 XP009031347	

Examiner Signature	/Hemant Khanna/	Date Considered	04/06/2007
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.